



Andreas Wildi

Dr. med. et lic. iur. HSG, Attorney at Law
Partner
Phone +41 58 658 29 15
andreas.wildi@walderwyss.com



Andreas Wildi, born 1972, is a medical doctor and an attorney at law.

He advises and represents companies, associations and NGOs in the life sciences and healthcare sector.

His main focus is on reimbursement and pricing as well as regulatory affairs relating to pharmaceuticals and medical devices.

Andreas Wildi studied medicine at the University of Zurich and received his doctorate (Dr. med. / MD). While working part-time as a doctor in a hospital, in international rescue services and assisting / substituting general practitioners, he completed his law studies at the University of St. Gallen HSG (lic. iur. HSG). Before being admitted to the bar, Andreas Wildi was a clerk at a Cantonal Court and a trainee in a recognized Zurich business law firm. From his first position as an attorney at law in a large Zurich business law firm, Andreas Wildi was asked to work for the Swiss Government, where he led the pharmaceutical reimbursement & pricing unit in the Federal Office of Public Health BAG. Andreas Wildi deepened his market access expertise internationally as EMEA market access law director for a large multinational life sciences company. Andreas Wildi has been a partner at Walder Wyss in Zurich and Berne since 2015.

Andreas Wildi works in German, English and French. He is admitted to the bar before all courts in Switzerland and is a guest lecturer in pharmaceutical law at the Law Faculty of the University of Lucerne and at the University of Bern's KPM Center for Public Management.

Selected Publications

Swiss pharmaceutical reimbursement and pricing: Ordinance Law Changes (KVV/KLV) as of January 2024: Today's Decision by the Swiss Federal Council (Bundesrat)

by Andreas Wildi and Celine Weber
September 2023

Handbuch zum Lebensmittel- und Gebrauchsgegenständerecht
[Handbook on Foodstuffs and Utility Articles law]

by Annemarie Lagger, Andreas Wildi,
Sophie Regenfuss, Celine Weber,
Christine Leuch, Florian Roth, Hugh
Reeves, Monja Sieber and Pandora
Kunz-Notter

Editor[s]: Daniel Donauer, Hugh Reeves
und Celine Weber
Zürich, 2019

Triennial review of medicines' SL prices: Lessons learned from appeals won against the FOPH

by Celine Weber and Andreas Wildi
July 2023

The Revised Law on Human Genetic Testing

by Andreas Wildi, Lucina Herzog and
Simon Mazidi
in: Life Science Recht, pp. 31-38, March
2023

Zugang zu nicht zugelassenen/nicht gelisteten Arzneimitteln: Ein wahrer Irrgarten

[Access to unapproved/non-listed drugs: A veritable maze]
by Carole-Anne Baud, Reto Baumann,
Jean-Christophe Devaud, Valérie Junod
and Andreas Wildi
in: Aktuelle Juristische Praxis (AJP), pp.
176-182, January 2023

Pharmaceutical Advertising 2022 - Switzerland

by Andreas Wildi and Celine Weber
in: Chambers Global Practice Guide,
2022

Kommentar zu Art. 5, 6 und 7a HMG

[Commentary on Art. 5, 6 und 7a HMG]
by Michael Isler [co-author], Andreas
Wildi [co-author] and Stephanie
Eggimann [co-author]
in: Eichenberger/Jaisli/Richli (Editor[s]),
"Basler Kommentar zum
Heilmittelgesetz"
2, Basel, 2021

For a complete list of publications

please visit our website:

www.walderwyss.com/andreas.wildi